Bitrobius Genetics

Bitrobius Genetics is a biotechnology startup, founded in 2020, with a passionate vision of utilizing the Gentrafix™ platform to revolutionize gene therapy. The company's slogan, "Developing the Gentrafix platform technology to revolutionise gene therapy," underscores its commitment to addressing a critical limitation in gene therapy: the restricted reach of therapeutic genes to affected cells in organs or tissues. By leveraging this innovative platform, Bitrobius Genetics aims to overcome this challenge, offering potential breakthroughs in the treatment of genetic diseases. Bitrobius Genetics' recent achievement includes securing a Series A investment on 01 July 2021 from Future Planet Capital, signaling a notable milestone in its journey. This backing from renowned investors reflects confidence in the company's technological advancements, affirming its potential to redefine the landscape of gene therapy. With its focus on biotechnology and healthcare, Bitrobius Genetics is poised at the forefront of innovation, holding the promise of significant impact in the field of genetic disease treatment.